B-Cell Adult Acute Lymphocytic Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for B-Cell Adult Acute Lymphocytic Leukemia

MalaCards integrated aliases for B-Cell Adult Acute Lymphocytic Leukemia:

Name: B-Cell Adult Acute Lymphocytic Leukemia 12 15
Adult B Acute Lymphoblastic Leukemia 12 17
Adult B-Cell Acute Lymphoblastic Leukemia 12
B-Cell Adult Acute Lymphoblastic Leukemia 71
Adult B-Cell Lymphocytic Leukemia 12
Adult B-Lymphoblastic Leukemia 12


External Ids:

Disease Ontology 12 DOID:0060592
NCIt 49 C9143
UMLS 71 C0279593

Summaries for B-Cell Adult Acute Lymphocytic Leukemia

MalaCards based summary : B-Cell Adult Acute Lymphocytic Leukemia, also known as adult b acute lymphoblastic leukemia, is related to lymphocytic leukemia and precursor t-cell acute lymphoblastic leukemia, and has symptoms including bone pain An important gene associated with B-Cell Adult Acute Lymphocytic Leukemia is IKZF1 (IKAROS Family Zinc Finger 1), and among its related pathways/superpathways are Hematopoietic cell lineage and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include b cells, b lymphoblasts and t cells, and related phenotypes are hematopoietic system and immune system

Related Diseases for B-Cell Adult Acute Lymphocytic Leukemia

Diseases in the B-Cell Adult Acute Lymphocytic Leukemia family:

T-Cell Adult Acute Lymphocytic Leukemia

Diseases related to B-Cell Adult Acute Lymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 43)
# Related Disease Score Top Affiliating Genes
1 lymphocytic leukemia 30.1 IKZF1 BCR ANPEP ABL1
2 precursor t-cell acute lymphoblastic leukemia 29.6 IKZF1 BCR ANPEP ABL1
3 acute leukemia 29.4 CD22 BCR ANPEP
4 leukemia, acute lymphoblastic 3 29.3 IKZF1 CD19 BCR ANPEP ABL1
5 myeloma, multiple 29.3 IKZF1 CD22 CD19 ABL1
6 leukemia, chronic lymphocytic 28.4 CD22 CD19 BCR ABL1
7 leukemia, acute lymphoblastic 27.8 IKZF1 CEACAM6 CD22 CD19 BCR ANPEP
8 leukemia, acute myeloid 27.8 IKZF1 EVPL CD22 CD19 BCR ANPEP
9 philadelphia-negative chronic myeloid leukemia 10.2 BCR ABL1
10 myelophthisic anemia 10.1 ANPEP ABL1
11 myelodysplastic syndrome 10.1
12 graft-versus-host disease 10.1
13 mucositis 10.1
14 neutropenia 10.1
15 acute t cell leukemia 10.1
16 lymphopenia 10.1
17 47,xyy 10.1
18 acute graft versus host disease 10.1
19 chromosomal triplication 10.1
20 splenomegaly 10.1
21 leukemia 10.0
22 mental retardation, autosomal dominant 33 10.0 IKZF1 CD22 ABL1
23 precursor b lymphoblastic lymphoma/leukemia 10.0
24 posttransplant acute limbic encephalitis 10.0
25 monoclonal paraproteinemia 9.9 CD22 CD19
26 refractory hematologic cancer 9.9 CD22 CD19
27 refractory hairy cell leukemia 9.9 CD22 CD19
28 central nervous system leukemia 9.9 CD19 ANPEP
29 eye lymphoma 9.9 CD22 CD19
30 relapsed/refractory diffuse large b-cell lymphoma 9.9 CD22 CD19
31 waldenstroem's macroglobulinemia 9.8 CD22 CD19
32 adult lymphoma 9.8 CD22 CD19
33 alpha chain disease 9.8 CD22 CD19
34 cll/sll 9.7 CD22 CD19
35 capillary leak syndrome 9.7 CD22 CD19
36 myeloproliferative neoplasm 9.6 BCR ANPEP ABL1
37 plasma protein metabolism disease 9.5 CD22 CD19
38 b-cell lymphoma 9.3 IKZF1 CD22 CD19 BCR
39 pancytopenia 9.3 IKZF1 CD22 CD19 ANPEP
40 burkitt lymphoma 9.3 CD22 CD19 BCR ABL1
41 lymphoma, non-hodgkin, familial 9.2 IKZF1 CD22 CD19 BCR
42 hematologic cancer 9.2 IKZF1 CD22 CD19 BCR ABL1
43 leukemia, chronic myeloid 8.9 IKZF1 EVPL CD19 BCR ANPEP ABL1

Graphical network of the top 20 diseases related to B-Cell Adult Acute Lymphocytic Leukemia:

Diseases related to B-Cell Adult Acute Lymphocytic Leukemia

Symptoms & Phenotypes for B-Cell Adult Acute Lymphocytic Leukemia

UMLS symptoms related to B-Cell Adult Acute Lymphocytic Leukemia:

bone pain

MGI Mouse Phenotypes related to B-Cell Adult Acute Lymphocytic Leukemia:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.61 ABL1 ANPEP BCR CD19 CD22 IKZF1
2 immune system MP:0005387 9.28 ABL1 ANPEP BCR CD19 CD22 IKZF1

Drugs & Therapeutics for B-Cell Adult Acute Lymphocytic Leukemia

Drugs for B-Cell Adult Acute Lymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
7 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
Ifosfamide Approved Phase 3 3778-73-2 3690
Thioguanine Approved Phase 3 154-42-7 2723601
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
Lenograstim Approved, Investigational Phase 3 135968-09-1
Hydrocortisone acetate Approved, Vet_approved Phase 2, Phase 3 50-03-3
Hydrocortisone Approved, Vet_approved Phase 2, Phase 3 50-23-7 5754
Carmustine Approved, Investigational Phase 3 154-93-8 2578
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
Ichthammol Approved Phase 2, Phase 3 8029-68-3
Dasatinib Approved, Investigational Phase 2, Phase 3 302962-49-8 3062316
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
Daunorubicin Approved Phase 3 20830-81-3 30323
leucovorin Approved Phase 3 58-05-9 6006 143
Mercaptopurine Approved Phase 3 50-44-2 667490
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
Etoposide Approved Phase 3 33419-42-0 36462
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
rituximab Approved Phase 3 174722-31-7 10201696
Pegaspargase Approved, Investigational Phase 3 130167-69-0
Melphalan Approved Phase 3 148-82-3 4053 460612
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
Aspartic acid Approved, Nutraceutical Phase 2, Phase 3 56-84-8 5960
Tyrosine Approved, Investigational, Nutraceutical Phase 2, Phase 3 60-18-4 6057
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
Emodepside Investigational, Vet_approved Phase 2, Phase 3 155030-63-0
Cortisone Experimental Phase 2, Phase 3 53-06-5 222786
42 Antiemetics Phase 3
43 Gastrointestinal Agents Phase 3
44 HIV Protease Inhibitors Phase 3
protease inhibitors Phase 3
46 Anti-Inflammatory Agents Phase 3
47 BB 1101 Phase 3
48 Autonomic Agents Phase 3
49 Hormone Antagonists Phase 3
50 Antineoplastic Agents, Hormonal Phase 3

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 A Pilot Study of Dose Intensification of Methotrexate in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkins Lymphoma and B-Cell All Completed NCT00005977 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate
2 A Phase III Trial Comparing ARA-C/High-Dose Mitoxantrone ("ALL-2') to A Standard Vincristine/Prednisone Based Regimen ('L-20') as Induction Therapy For Adult Patients With Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol Completed NCT00002766 Phase 3 carmustine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;doxorubicin hydrochloride;etoposide;mercaptopurine;methotrexate;mitoxantrone hydrochloride;pegaspargase;prednisone;vincristine sulfate
3 High Risk B-Precursor Acute Lymphoblastic Leukemia Completed NCT00075725 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine sulfate
4 Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) Completed NCT00720109 Phase 2, Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Dasatinib;Daunorubicin Hydrochloride;Dexamethasone;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisone;Vincristine Sulfate
5 A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia Recruiting NCT01085617 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;imatinib mesylate;melphalan;mercaptopurine;methotrexate;nelarabine;pegaspargase;vincristine sulfate
6 MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93) Unknown status NCT00002531 Phase 2 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;mercaptopurine;methotrexate;mitoxantrone hydrochloride;prednisolone;teniposide;thioguanine;vincristine sulfate;vindesine
7 A Phase II Trial of 506U78 (IND 52611) in Patients With Relapsed or Refractory Non T-cell Acute Lymphoblastic Leukemia (ALL) Completed NCT00006020 Phase 2 nelarabine
8 Phase II Study of Adult Acute Lymphoblastic Leukaemia (ALL): Imatinib in Combination With Chemotherapy in Ph+ Patients, and Post-remissional Treatment Intensification in High-risk Ph- Patients, With Minimal Residual Disease Monitoring. Completed NCT00458848 Phase 2 asparaginase;daunorubicin hydrochloride;etoposide;idarubicin;imatinib mesylate;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
9 A Phase I/II Study of Combined Enrichment of CD34+ Cells and Depletion of B-Cells From Peripheral Blood Stem Cell Components for Patients With B-Lymphoid Malignancies Completed NCT00003874 Phase 1, Phase 2
10 Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies Completed NCT00867529 Phase 2
11 S0910, A Phase II Study of Epratuzumab (NSC-716711) in Combination With Cytarabine and Clofarabine for Patients With Relapsed or Refractory Ph- Negative Precursor B-Cell Acute Lymphoblastic Leukemia Completed NCT00945815 Phase 2 clofarabine;cytarabine
12 A Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy (VXLD) for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Completed NCT01769209 Phase 2 Bortezomib;Doxorubicin hydrochloride (HCl);PEG-Asparaginase;Vincristine sulfate;Dexamethasone;Cytarabine;Methotrexate
13 Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With High-Dose 90Y-Labeled Humanized LL2 Anti-CD-22 Antibody and Peripheral Blood Stem Cell Rescue Completed NCT00004107 Phase 1, Phase 2
14 Phase II Trial of Intensive, Short-Course Combination Chemotherapy in the Treatment of Newly Diagnosed Patients With Poor-Risk Nonlymphoblastic Lymphoma and Acute B-Lymphoblastic Leukemia and in Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00002471 Phase 2 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;leucovorin calcium;methotrexate;methylprednisolone;therapeutic hydrocortisone;thiotepa;vincristine sulfate
15 A Phase II Trial of Cytarabine and Clofarabine in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Completed NCT00337168 Phase 2 clofarabine;cytarabine
16 A Phase II Pilot Trial of Bortezomib (PS-341, Velcade) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) Completed NCT00873093 Phase 2 L-asparaginase;doxorubicin hydrochloride;therapeutic hydrocortisone;vincristine sulfate;cytarabine;prednisone;bortezomib;pegaspargase;methotrexate;etoposide phosphate;cyclophosphamide;leucovorin calcium;High Dose MTX
17 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
18 A Phase 2 Study of Ibrutinib and Blinatumomab in Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia Recruiting NCT02997761 Phase 2 Ibrutinib
19 An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL) Active, not recruiting NCT00558519 Phase 2 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;thioguanine;vincristine sulfate
20 Blinatumomab for Minimal Residual Disease (MRD) in Pre-B Cell Acute Lymphoblastic Leukemia Patients Following Hematopoietic Cell Transplantation: A Canadian, Multicentre Trial Not yet recruiting NCT04044560 Phase 2
21 A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL) Terminated NCT02129062 Phase 2 Ibrutinib
22 A Phase I/II Trial of Romidepsin, Rituximab and Lenalidomide (R3) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma Withdrawn NCT02281279 Phase 1, Phase 2 lenalidomide;romidepsin
23 A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage Withdrawn NCT01670084 Phase 2 nilotinib;cyclophosphamide;doxorubicin hydrochloride;vincristine sulfate;methotrexate;cytarabine;prednisone;mesna;dexamethasone;leucovorin calcium
24 Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults Completed NCT02228772 Phase 1 MLN 9708;Vincristine;Cytarabine;Doxorubicin;Mercaptopurine;Cyclophosphamide;Methotrexate
25 A Phase I Trial Of Rituximab And Interleukin-2 Completed NCT00010192 Phase 1
26 Phase I Study of Adoptive Immunotherapy With CD8 Minor Histocompatibility (H) Antigen-Specific CTL Clones for Patients With Relapsed of AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant Completed NCT00107354 Phase 1 cytarabine;etoposide;mitoxantrone hydrochloride
27 Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies Completed NCT01567709 Phase 1 Alisertib;Vorinostat
28 A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma Completed NCT00889408 Phase 1
29 A Phase I Study of Photochemically Treated Donor T-Cell Supplements in HLA Haplotype Mismatched Hematopoietic Stem Cell Transplantation Completed NCT00005092 Phase 1 Cyclophosphamide;Psoralen;Thiotepa
30 A Phase I Trial of Palbociclib in Combination With Dexamethasone in Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia (ALL) Recruiting NCT03472573 Phase 1 Palbociclib;Dexamethasone
31 A Phase I Study of Administrating CD19 Chimeric Antigen Receptor Expressing T Cells Followed by Allogeneic Stem Cell Transplantation in Patients With Refractory CD19+ B-linage Leukemia/Lymphoma Recruiting NCT03110640 Phase 1 Fludarabine;Cyclophosphamide
32 A Phase I Study of Combination Therapy With Anti-CD19 and Anti-CD22 Immunotoxins (Combotox) in Adults With Refractory/Relapse Acute Lymphoblastic Leukemia Recruiting NCT00450944 Phase 1
33 A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells Bearing a Human Binding Domain, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia Recruiting NCT03103971 Phase 1 Cyclophosphamide;Fludarabine
34 Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With High-Risk CD19+ Acute Lymphoblastic Leukemia Recruiting NCT02146924 Phase 1
35 Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine and Rituximab, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Terminated NCT02168907 Phase 1 6,8-bis(benzylthio)octanoic acid;bendamustine hydrochloride
36 Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma Terminated NCT02109224 Phase 1 Ibrutinib
37 A Phase 1 Study of the Deglycosylated Ricin A Chain-containing Combined Anti-CD19 and Anti-CD22 Immunotoxin Combotox in Combination With High-Dose Cytarabine in Adult Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia Terminated NCT01408160 Phase 1 Cytarabine
38 Genomic Analysis of Adolescent and Young Adult Acute Lymphoblastic Leukemia Unknown status NCT01653613
39 Micro RNA Expression Analysis in B-Lineage Adult Acute Lymphoblastic Leukemia From ALL Trial, E2993, Including Patients With Various Cytogenetic and Molecular Abnormalities Completed NCT01505699
40 Identifying Rare Genetic Variants Involved in High Risk Acute Lymphoblastic Leukemia (ALL) Via Pooled DNA Sequencing Completed NCT01119586
41 Young Adult Acute Lymphoid Leukemia (ALL): Intensification of Pediatric AIEOP LLA-2000 Treatment Completed NCT01156883 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;ifosfamide;mercaptopurine;methotrexate;methylprednisolone;prednisone;thioguanine;vincristine sulfate;vindesine
42 Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study Completed NCT00866307 pegaspargase;cytarabine;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide;prednisone;dexamethasone;methotrexate;daunorubicin hydrochloride;mercaptopurine;thioguanine
43 A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-asparaginase, IND# 100594) or Intravenous Oncaspar® in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia (ALL) Completed NCT00671034 calaspargase pegol;calaspargase pegol;Pegaspargase;DOXOrubicin Hydrochloride;Cytarabine;Prednisone;methotrexate;cyclophosphamide;mercaptopurine tablet;Dexamethasone;thioguanine;DAUNOrubicin Hydrochloride;vincristine sulfate
44 Multicenter Trial Treatment of Philadelphia Chromosome Negative (Ph-) B-lineage Acute Lymphoblastic Leukemia (ALL) of Young Adults (18-59 Years). Recruiting NCT02617004
45 A Phase I Study of Vaccination With Autologous CD40-Activated Acute Lymphoblastic Leukemia Cells Terminated NCT00020670 Early Phase 1

Search NIH Clinical Center for B-Cell Adult Acute Lymphocytic Leukemia

Genetic Tests for B-Cell Adult Acute Lymphocytic Leukemia

Anatomical Context for B-Cell Adult Acute Lymphocytic Leukemia

MalaCards organs/tissues related to B-Cell Adult Acute Lymphocytic Leukemia:

B Cells, B Lymphoblasts, T Cells, Myeloid, Bone, Eye

Publications for B-Cell Adult Acute Lymphocytic Leukemia

Articles related to B-Cell Adult Acute Lymphocytic Leukemia:

# Title Authors PMID Year
Suppression of miR-708 inhibits the Wnt/β-catenin signaling pathway by activating DKK3 in adult B-all. 61
28969056 2017
Atypical BCR-ABL1 fusion transcripts in adult B-acute lymphoblastic leukemia, including a novel fusion transcript-e8a1. 61
26942999 2016
Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia. 61
27559941 2016
Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia. 61
26921100 2016
Prognostic significance of MSI2 predicts unfavorable outcome in adult B-acute lymphoblastic leukemia. 61
25090928 2015
BCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemia. 61
26045902 2015
Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia. 61
23955588 2013
Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. 61
23107779 2012
Fingerprinting acute leukemia: DNA methylation profiling of B-acute lymphoblastic leukemia. 61
23148371 2012

Variations for B-Cell Adult Acute Lymphocytic Leukemia

Expression for B-Cell Adult Acute Lymphocytic Leukemia

Search GEO for disease gene expression data for B-Cell Adult Acute Lymphocytic Leukemia.

Pathways for B-Cell Adult Acute Lymphocytic Leukemia

Pathways related to B-Cell Adult Acute Lymphocytic Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.13 CD22 CD19 ANPEP
2 10.99 CEACAM6 CD22 CD19 ANPEP

GO Terms for B-Cell Adult Acute Lymphocytic Leukemia

Biological processes related to B-Cell Adult Acute Lymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet-derived growth factor receptor signaling pathway GO:0048008 9.26 BCR ABL1
2 regulation of endocytosis GO:0030100 9.16 CD22 ABL1
3 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 8.96 CD19 ABL1
4 B cell proliferation involved in immune response GO:0002322 8.62 CD19 ABL1

Sources for B-Cell Adult Acute Lymphocytic Leukemia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....